Watch for actual ATM sales disclosures in upcoming 10-Qs to gauge dilution pace. The activist 3i, LP's recent purchases near current prices suggest potential for further pressure or strategic alternatives. Monitor for any prospectus supplement pricing an underwritten offering under the $100M shelf.
Price Chart
Executive Summary
Valion Bio filed an S-3 shelf registration statement to register up to $100M in securities, including a $5M ATM facility with Rodman & Renshaw. The filing follows recent activist stake accumulation by 3i, LP and a 1-for-25 reverse stock split on August 31, 2026. The company has a going-concern qualification from its auditors and had a negative tangible book value of approximately $(11.9M) as of June 30, 2026, making this a capital raise under significant financial distress and activist pressure.
Key Financial Metrics
Key Facts
- S-3 shelf registers up to $100M in securities, with a $5M ATM component through Rodman & Renshaw at 3.0% commission
- Non-affiliate market value was ~$15.1M as of October 7, 2026, capping I.B.6 sales at ~$5M in any 12-month period
- Auditors included a going-concern explanatory paragraph in the most recent annual report
- Net tangible book value deficit was $(11.9M) as of June 30, 2026; pro forma after full $5M ATM would be $(7.4M)
- Activist 3i, LP has been accumulating shares, with purchases as recent as September 3, 2026 at ~$2.88-$2.92 per share
- Reverse stock split 1-for-25 implemented August 31, 2026 to maintain Nasdaq listing
- Stock closed at $2.48 on October 5, 2026, down from $7.75 reference price used for non-affiliate calculation
- Outstanding convertible preferred shares (Series A, B, C) represent massive potential dilution: ~8.5M common shares issuable upon conversion
Financial Impact
Up to $5M in gross proceeds from ATM; potential for significant dilution given ~$15M non-affiliate market cap
Risk Factors
- Massive dilution from existing convertible preferred stock (~8.5M shares) and potential new issuance under shelf
- Going-concern qualification signals high risk of equity raise being a desperation measure
- Activist 3i, LP may push for changes that could include sale or restructuring
- Stock already down ~68% from the reference price used in the filing
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001683168-26-007707 |
| Document: valion_ex0402.htm | 0001683168-26-007707 |
| Document: valion_ex0102.htm | 0001683168-26-007707 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.7820 (+12.63%) |
Oct 26, 2026 1d ago | 8-K | $0.8400 | awaiting T+20 | — | $0.7820 (−6.90%) |
Oct 22, 2026 5d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.7820 (−18.20%) |
Oct 21, 2026 7d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 21, 2026 7d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 16, 2026 11d ago | S-3 | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 16, 2026 11d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 15, 2026 12d ago | 8-K | $1.23 | awaiting T+20 | — | $0.7820 (−36.42%) |
Oct 14, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $0.7820 (−46.07%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.7820 (+64.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers